Alumis Inc.
ALMS
Rank in Stocks
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.15
Last synced: 2026-10-16
Market Cap
$795.38M
Change (1 day)
-2.61%
Change (1 year)
170.70%
Country
US
Trade Alumis Inc. (ALMS)
Category
Healthcare
Market Capitalization of Alumis Inc.(ALMS)
Market Cap: $795.38M
As of October 2026 Alumis Inc. has a market cap of $795.38M. This makes Alumis Inc. the world's 10425th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Alumis Inc. from 2023 to 2026
ALMS compared with Top 5 Most Popular stocks
